Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx abuse monitoring law

Executive Summary

President Bush signs the "National All Schedules Prescription Electronic Reporting Act" into law Aug. 11. The law, which passed the House July 27 and the Senate July 29, authorizes $60 mil. over fiscal years 2006-2010 for states to create or augment monitoring systems to track prescriptions of Schedule II-IV drugs across state lines (1"The Pink Sheet" Aug. 8, 2005, p. 27). The monitoring programs will require healthcare providers to report the dispensation of controlled substances within a week. Following a public comment period, the Secretary of HHS will establish minimum requirements, including certain privacy provisions, that states must meet in order to be eligible for grants under the law...

You may also be interested in...



Importation Limits In Future Trade Agreements Prevented Under Vitter Bill

Pharmaceutical importation prohibitions in future U.S. trade agreements would be forbidden under a bill co-sponsored by Sens. David Vitter (R-La.) and Debbie Stabenow (D-Mich.)

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

BMS Has A Strong Pipeline, But Access Challenges Remain

Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046265

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel